For traders, this data de-risks MICVO's monotherapy profile and sets a clear catalyst path: combo data (Q4 2026), End of Phase 2 meeting (Q1 2027), updated overall survival (1H 2027), and Phase 3 initiation (mid-2027). Monitor for any safety signals as the trial expands (peripheral neuropathy Gr3 in 17.1% of patients).
Drug in focus
PYXS drug pipeline →PYX-201
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 1 / Phase 1/2
- Time to market
- At least 2-3 years, assuming Phase 3 trial (planned mid-2027) succeeds and leads to an NDA filing. No regulatory filing has occurred yet.
- Next catalyst
- None dated
What to watchThe next near-term catalyst is the EORTC-NCI-AACR late-breaking oral presentation (Nov 18-20, 2026), though the top-line data has already been disclosed. The true binary events are: Q4 2026 updated combo data, Q1 2027 End-of-Phase 2 meeting with FDA, and H1 2027 overall survival data from the monotherapy study, any of which could drive major moves. The $3.50 common warrant exercise trigger (requiring both shareholder approval and OS data) creates an additional overhang that could cap upside until clarity emerges.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 9 $3.38entry
- T+1 · 2mo ago −3.25%α −2.65% · $3.27
- T+5 · 2mo ago −1.18%α −0.09% · $3.34
- T+20 · 6w ago −40.53%α −42.48% · $2.01
- T+48 · todayOpen
- T+60 · in 16d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pyxis Oncology announced positive updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The data show a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months, and a 12-month overall survival probability of 79%, substantially exceeding historical control benchmarks. Safety was manageable with dose capping, supporting advancement into a pivotal Phase 3 trial (Headliner) planned for mid-2027.
Key Facts
- 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR) in 2L+ R/M HNSCC (N=33 efficacy evaluable)
- Median progression-free survival (mPFS) of 6.2 months; 12-month overall survival probability of 79% (median OS not yet reached)
- Clinical activity observed across HPV status and prior-treatment subgroups, including prior EGFRi-exposed patients
- No new safety signals; dose capping reduced frequency and severity of adverse events, especially peripheral neuropathy
- Phase 3 Headliner trial planned for mid-2027; End of Phase 2 meeting with FDA expected Q1 2027
- Updated data from MICVO + KEYTRUDA (pembrolizumab) combination in 1L R/M HNSCC expected Q4 2026
Financial Impact
No financial data in filing; positive clinical data supports potential for a multi-billion-dollar addressable market (>$4B US TAM in 2L+ HNSCC per company estimates) but revenue still zero as company is pre-commercial
Risk Factors
- Early stage: Phase 1 data, small sample size (N=33 efficacy evaluable), and cross-trial comparisons are not head-to-head
- Safety: Grade 3 peripheral neuropathy in 17.1% and 14% discontinuation rate; need to monitor in larger Phase 3
- Competitive landscape: novel EGFRi therapies (e.g., petosemtamab) may shift 1L treatment and affect 2L+ trial enrollment
- Regulatory risk: Phase 3 design requires alignment with FDA on dose selection (Project Optimus) and co-primary endpoints (ORR and OS)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-385901 |
| Document: pyxs-ex99_1.htm | 0001193125-26-385901 |
| Document: pyxs-ex99_2.htm | 0001193125-26-385901 |
| Document: 0001193125-26-385901-index-headers.html | 0001193125-26-385901 |
| Document: 0001193125-26-385901-index.html | 0001193125-26-385901 |
| Document: 0001193125-26-385901.txt | 0001193125-26-385901 |
Track record
25 reports on PYXS
6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
- Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
- Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
- Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
- Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
- Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers